4.6 Article

The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

Journal

CANCER IMMUNOLOGY RESEARCH
Volume 9, Issue 1, Pages 75-88

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-20-0236

Keywords

-

Funding

  1. NCI of the NIH [P30CA033572]
  2. Toni Stephenson Lymphoma Center
  3. Leukemia & Lymphoma Society Mantle Cell Lymphoma Research Initiative [SCOR 7000-18]
  4. U.S. Department of Defense [CA170783]
  5. Borstein Family Foundation

Ask authors/readers for more resources

The study demonstrated that intracerebroventricular (ICV) delivery of CD19-CAR T cells had activity against both CNS and systemic lymphomas in a mouse model, suggesting a valuable new strategy for treating B-cell malignancies with CNS involvement.
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than those without CNS involvement, and patients currently have limited treatment options. T cells genetically engineered with CD19-targeted chimeric antigen receptors (CAR) are effective against B-cell malignancies and show tremendous potential in the treatment of systemic lymphoma. We aimed to leverage this strategy toward a more effective therapy for patients with lymphoma with CNS disease. NOD-scid IL2Rgamma(null) (NSG) mice with CNS and/or systemic lymphoma were treated with CD 19-CART cells via intracerebroventricular (ICV) or intravenous (IV) injection. CAR T cells isolated after treatment were rigorously examined for phenotype, gene expression, and function. We observed that CART cells infused ICV, but not IV, completely and durably eradicated both CNS and systemic lymphoma. CAR T cells delivered ICV migrated efficiently to the periphery, homed to systemic tumors, and expanded in vivo, leading to complete elimination of disease and resistance to tumor rechallenge. Mechanistic studies indicated that ICV-delivered CAR T cells are conditioned by exposure to cerebrospinal fluid in the ICV environment for superior antilymphoma activity and memory function compared with IV-delivered CART cells. Further analysis suggested that manipulating cellular metabolism or preactivating therapeutic CAR T cells with antigen ex vivo may improve the efficacy of CART cells in vivo. Our demonstration that ICV-delivered CD19-CAR T cells had activity against CNS and systemic lymphoma could offer a valuable new strategy for treatment of B-cell malignancies with CNS involvement.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available